In addition, given the minimal success of EGFR targeting strategy and the commonly occurring resistance24, the need for additional treatment options that improve outcome of existing therapeutic tactics for HNSCC is pressing. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.